Effect of risedronate on femoral periprosthetic bone loss following total hip replacement: A systematic review and meta-analysis
- PMID: 29702983
- PMCID: PMC5944478
- DOI: 10.1097/MD.0000000000010379
Effect of risedronate on femoral periprosthetic bone loss following total hip replacement: A systematic review and meta-analysis
Abstract
Background: Recent study has reported that risedronate was effective in reducing periprosthesis bone loss after total hip arthroplasty (THA). The meta-analysis was performed to compare the clinical outcomes of THA with oral risedronate versus placebo.
Methods: Electronic databases: PubMed (1950-March 2018), EMBASE (1974-March 2018), the Cochrane Central Register of Controlled Trials, Web of Science (1950-March 2018) were systematically searched. Two authors independently graded the methodological quality of each eligible study using the Cochrane Collaboration tool and extracted relevant data. Statistical heterogeneity among the trials were evaluated with chi-square and I-square tests. This meta-analysis was performed using STATA 14.0.
Results: A total of 4 randomized controlled trials (RCTs) published between 2006 and 2015 were included in our study. The meta-analysis demonstrated that risedronate was associated with a significantly reduction of periprosthetic bone mineral density after THA. No increased postoperative complications were observed.
Conclusion: Oral risedronate might reduce the periprosthetic bone resorption after cementless THA. Additionally, no severe adverse effects were observed. High-quality RCTs with large sample size were still required.
Conflict of interest statement
The authors declare that there is no competing interests.
Figures











Similar articles
-
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty: A systematic review and meta-analysis.Int J Surg. 2018 Apr;52:189-200. doi: 10.1016/j.ijsu.2018.02.007. Epub 2018 Feb 12. Int J Surg. 2018. PMID: 29448032
-
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.Cochrane Database Syst Rev. 2022 May 3;5(5):CD004523. doi: 10.1002/14651858.CD004523.pub4. Cochrane Database Syst Rev. 2022. PMID: 35502787 Free PMC article.
-
Anti-osteoporotic drug efficacy for periprosthetic bone loss after total hip arthroplasty: A systematic review and network meta-analysis.J Orthop Sci. 2025 Jan;30(1):126-135. doi: 10.1016/j.jos.2024.01.011. Epub 2024 Feb 10. J Orthop Sci. 2025. PMID: 38342711
-
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.Health Technol Assess. 2005 Jun;9(22):1-160. doi: 10.3310/hta9220. Health Technol Assess. 2005. PMID: 15929857
-
Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials.Arch Osteoporos. 2023 Feb 25;18(1):37. doi: 10.1007/s11657-023-01227-9. Arch Osteoporos. 2023. PMID: 36840811
Cited by
-
The use of bisphosphonates after joint arthroplasty is associated with lower implant revision rate.Knee Surg Sports Traumatol Arthrosc. 2019 Jul;27(7):2082-2089. doi: 10.1007/s00167-018-5333-4. Epub 2018 Dec 13. Knee Surg Sports Traumatol Arthrosc. 2019. PMID: 30547306
-
The lexicon for periprosthetic bone loss versus osteolysis after cervical disc arthroplasty: a systematic review.Eur Spine J. 2022 Apr;31(4):830-842. doi: 10.1007/s00586-021-07092-9. Epub 2022 Jan 9. Eur Spine J. 2022. PMID: 34999945
-
Letter to the Editor: Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis.J Orthop Surg Res. 2022 Jan 5;17(1):8. doi: 10.1186/s13018-021-02891-8. J Orthop Surg Res. 2022. PMID: 34986846 Free PMC article. No abstract available.
-
Bench-to-bedside strategies for osteoporotic fracture: From osteoimmunology to mechanosensation.Bone Res. 2019 Aug 15;7:25. doi: 10.1038/s41413-019-0066-7. eCollection 2019. Bone Res. 2019. PMID: 31646015 Free PMC article. Review.
-
Efficacy of risedronate in improving bone mineral density in patients undergoing total hip arthroplasty: A meta-analysis of randomized controlled trials.Medicine (Baltimore). 2018 Dec;97(51):e13346. doi: 10.1097/MD.0000000000013346. Medicine (Baltimore). 2018. PMID: 30572438 Free PMC article.
References
-
- Kawamura H, Mishima H, Sugaya H, et al. The 21- to 27-year results of the Harris-Galante cementless total hip arthroplasty. J Orthop Sci 2016;21:342–7. - PubMed
-
- Tran P, Zhang BX, Lade JA, et al. Periprosthetic bone remodeling after novel short-stem neck-sparing total hip arthroplasty. J Arthroplasty 2016;31:2530–5. - PubMed
-
- Bugbee WD, Culpepper WJ, 2nd, Engh CA, Jr, et al. Long-term clinical consequences of stress-shielding after total hip arthroplasty without cement. J Bone Joint Surg Am 1997;79:1007–12. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical